Radiotherapy & Oncology
Volume 81, Issue 2 , Pages 119-121 , November 2006

Tumour hypoxia – A characteristic feature with a complex molecular background

  • Jesper Grau Eriksen

      Affiliations

    • Corresponding Author InformationCorresponding author. Jesper Grau Eriksen, Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade 44, build.5 8000 Aarhus C, Denmark.
    • ,
  • Michael R. Horsman

Received 16 September 2006 ,Accepted 20 September 2006.

References 

  1. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449–6465
  2. Horsman MR, Overgaard J. The oxygen effect and tumour microenviroment. In:  Steel GG editors. Basic clinical radiobiology. London: Arnold; 2002;p. 58–168
  3. Horsman MR, Overgaard J. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen. Radiother Oncol. 2004;70:301–309
  4. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the danish head and neck cancer study (DAHANCA) protocol 5-85. Radiother Oncol. 1998;46:135–146
  5. Fenton BM, Paoni SF, Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol. 2004;72:221–230
  6. Horsman MR, Overgaard J. Overcoming tumour radioresistance resulting from hypoxia. In:  Steel GG editors. Basic clinical radiobiology. London: Arnold; 2002;p. 58–168
  7. Rischin D, Peters L, Fisher R, et al. Tirapazamine, cisplatin, and radiation versus fluro-uracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02). J Clin Onvol. 2005;23:79–87
  8. Le QT, Taira A, Budenz S, et al. Mature results from a randomized phase II trial of cis-platin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas. Cancer. 2006;106:1940–1949
  9. Horsman MR. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys. 1998;42:701–704
  10. Salmon HW, Siemann DW. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiother Oncol. 2004;73:359–366
  11. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol. 2005;77:18–24
  12. Koritzinsky M, Seigneuric R, Magagnin MG, van den BT, Lambin P, Wouters BG. The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol. 2005;76:177–186
  13. Sorensen BS, Hao J, Overgaard J, et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol. 2005;76:187–193
  14. Hoskin PJ, Sibtain A, Daley FM, Saunders MI, Wilson GD. The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiother Oncol. 2004;72:159–168
  15. Janssen HL, Hoebers FJ, Sprong D, et al. Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. Radiother Oncol. 2004;70:91–97
  16. Yaromina A, Zips D, Thames HD, et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. Radiother Oncol. 2006;81:122–129
  17. Yaromina A, Holscher T, Eicheler W, et al. Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. Radiother Oncol. 2005;76:206–212
  18. Quennet V, Yaromina A, Zips D, et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol. 2006;81:130–135
  19. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol. 2006;24:727–735
  20. Jonathan RA, Wijffels KI, Peeters W, et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol. 2006;79:288–297
  21. Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1α and 2α, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 2002;8:2595–2604
  22. Brurberg KG, Skogmo HK, Graff BA, Olsen DR, Rofstad EK. Fluctuations in pO2 in poorly and well-oxygenated spontaneous canine tumors before and during fractionated radiation therapy. Radiother Oncol. 2005;77:220–226
  23. Petersen C, Eicheler W, Frommel A, et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol. 2003;79:469–477
  24. Troost EG, Bussink J, Kaanders JH, et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol. 2005;76:194–199
  25. Buffa FM, Bentzen SM, Daley FM, et al. Molecular profiles predict loco-regional control of head and neck squamous cell carcinoma in a randomised trial of conventional versus continous hyperfractionated accelerated radiotherapy (CHART). Clin Cancer Res. 2004;
  26. Eriksen JG, Buffa FM, Alsner J, Steiniche T, Bentzen SM, Overgaard J. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother Oncol. 2004;72:275–282
  27. Weinmann M, Belka C, Guner D, et al. Array-based comparative gene expression analysis of tumor cells with increased apoptosis resistance after hypoxic selection. Oncogene. 2005;24:5914–5922

PII: S0167-8140(06)00483-X

doi: 10.1016/j.radonc.2006.09.005

Radiotherapy & Oncology
Volume 81, Issue 2 , Pages 119-121 , November 2006

Article Tools